6533b821fe1ef96bd127c02e

RESEARCH PRODUCT

EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.

Murielle MauerFlorian LordickChristoph SchumacherYoon-koo KangMarkus MoehlerNicole C.t. Van GriekenAjlan AtasoyHeike I. GrabschJolanda M. Van DierenManuel Salto-tellezMichela LiaAnna Dorothea WagnerJohanna W. Van SandickArnaud RothJae Yong Cho

subject

OncologyCisplatinCancer Researchmedicine.medical_specialtybusiness.industryImproved survivalCancermedicine.disease03 medical and health sciences0302 clinical medicineOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinePerioperative chemotherapymedicine030211 gastroenterology & hepatologyPertuzumabStomach cancerbusinessmedicine.drug

description

TPS4133Background: Approximately 10-20% of patients with gastric cancer (GCa) have HER-2 positive tumors. The addition of T to cisplatin/fluoropyrimidine-based CT improved survival in metastatic HE...

https://doi.org/10.1200/jco.2016.34.15_suppl.tps4133